207 related articles for article (PubMed ID: 21857027)
1. A discrete event modelling framework for simulation of long-term outcomes of sequential treatment strategies for ankylosing spondylitis.
Tran-Duy A; Boonen A; van de Laar MA; Franke AC; Severens JL
Ann Rheum Dis; 2011 Dec; 70(12):2111-8. PubMed ID: 21857027
[TBL] [Abstract][Full Text] [Related]
2. The burden of ankylosing spondylitis and the cost-effectiveness of treatment with infliximab (Remicade).
Kobelt G; Andlin-Sobocki P; Brophy S; Jönsson L; Calin A; Braun J
Rheumatology (Oxford); 2004 Sep; 43(9):1158-66. PubMed ID: 15226514
[TBL] [Abstract][Full Text] [Related]
3. Cost effectiveness of etanercept (Enbrel) in combination with methotrexate in the treatment of active rheumatoid arthritis based on the TEMPO trial.
Kobelt G; Lindgren P; Singh A; Klareskog L
Ann Rheum Dis; 2005 Aug; 64(8):1174-9. PubMed ID: 15708879
[TBL] [Abstract][Full Text] [Related]
4. Estimating the cost and health status consequences of treatment with TNF antagonists in patients with psoriatic arthritis.
Bansback NJ; Ara R; Barkham N; Brennan A; Fraser AD; Conway P; Reynolds A; Emery P
Rheumatology (Oxford); 2006 Aug; 45(8):1029-38. PubMed ID: 16782734
[TBL] [Abstract][Full Text] [Related]
5. The cost-effectiveness of infliximab (Remicade) in the treatment of ankylosing spondylitis in Canada.
Kobelt G; Andlin-Sobocki P; Maksymowych WP
J Rheumatol; 2006 Apr; 33(4):732-40. PubMed ID: 16583476
[TBL] [Abstract][Full Text] [Related]
6. Treatment strategies aiming at remission in early rheumatoid arthritis patients: starting with methotrexate monotherapy is cost-effective.
Schipper LG; Kievit W; den Broeder AA; van der Laar MA; Adang EM; Fransen J; van Riel PL
Rheumatology (Oxford); 2011 Jul; 50(7):1320-30. PubMed ID: 21371999
[TBL] [Abstract][Full Text] [Related]
7. The unmet need for anti-tumour necrosis factor (anti-TNF) therapy in ankylosing spondylitis.
Barkham N; Kong KO; Tennant A; Fraser A; Hensor E; Keenan AM; Emery P
Rheumatology (Oxford); 2005 Oct; 44(10):1277-81. PubMed ID: 16105913
[TBL] [Abstract][Full Text] [Related]
8. Costs and quality of life of patients with ankylosing spondylitis in Canada.
Kobelt G; Andlin-Sobocki P; Maksymowych WP
J Rheumatol; 2006 Feb; 33(2):289-95. PubMed ID: 16465660
[TBL] [Abstract][Full Text] [Related]
9. Cost-Effectiveness of Treatment Strategies with Biologics in Accordance with Treatment Guidelines for Ankylosing Spondylitis: A Patient-Level Model.
Le QA; Kang JH; Lee S; Delevry D
J Manag Care Spec Pharm; 2020 Oct; 26(10):1219-1231. PubMed ID: 32996395
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the Bath Ankylosing Spondylitis Disease Activity Index and a modified version of the index in assessing disease activity in patients with ankylosing spondylitis without peripheral manifestations.
Song IH; Rudwaleit M; Listing J; Sieper J
Ann Rheum Dis; 2009 Nov; 68(11):1701-7. PubMed ID: 19029168
[TBL] [Abstract][Full Text] [Related]
11. The cost-effectiveness of infliximab in the treatment of ankylosing spondylitis in Spain. Comparison of clinical trial and clinical practice data.
Kobelt G; Sobocki P; Mulero J; Gratacos J; Collantes-Estevez E; Braun J
Scand J Rheumatol; 2008; 37(1):62-71. PubMed ID: 18189197
[TBL] [Abstract][Full Text] [Related]
12. Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis.
Brandt J; Listing J; Haibel H; Sörensen H; Schwebig A; Rudwaleit M; Sieper J; Braun J
Rheumatology (Oxford); 2005 Mar; 44(3):342-8. PubMed ID: 15561737
[TBL] [Abstract][Full Text] [Related]
13. Cost effectiveness of adding leflunomide to a 5-year strategy of conventional disease-modifying antirheumatic drugs in patients with rheumatoid arthritis.
Maetzel A; Strand V; Tugwell P; Wells G; Bombardier C
Arthritis Rheum; 2002 Dec; 47(6):655-61. PubMed ID: 12522841
[TBL] [Abstract][Full Text] [Related]
14. Cost effectiveness of adalimumab for the treatment of ankylosing spondylitis in the United Kingdom.
Botteman MF; Hay JW; Luo MP; Curry AS; Wong RL; van Hout BA
Rheumatology (Oxford); 2007 Aug; 46(8):1320-8. PubMed ID: 17545684
[TBL] [Abstract][Full Text] [Related]
15. Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: results from 8 years' surveillance in the Danish nationwide DANBIO registry.
Glintborg B; Ostergaard M; Krogh NS; Dreyer L; Kristensen HL; Hetland ML
Ann Rheum Dis; 2010 Nov; 69(11):2002-8. PubMed ID: 20511613
[TBL] [Abstract][Full Text] [Related]
16. The cost-effectiveness of etanercept in patients with severe ankylosing spondylitis in the UK.
Ara RM; Reynolds AV; Conway P
Rheumatology (Oxford); 2007 Aug; 46(8):1338-44. PubMed ID: 17553909
[TBL] [Abstract][Full Text] [Related]
17. Modelling the effect of function and disease activity on costs and quality of life in rheumatoid arthritis.
Kobelt G; Lindgren P; Lindroth Y; Jacobson L; Eberhardt K
Rheumatology (Oxford); 2005 Sep; 44(9):1169-75. PubMed ID: 15956093
[TBL] [Abstract][Full Text] [Related]
18. Real life experience confirms sustained response to long-term biologics and switching in ankylosing spondylitis.
Coates LC; Cawkwell LS; Ng NW; Bennett AN; Bryer DJ; Fraser AD; Emery P; Marzo-Ortega H
Rheumatology (Oxford); 2008 Jun; 47(6):897-900. PubMed ID: 18403400
[TBL] [Abstract][Full Text] [Related]
19. Cost effectiveness of combined spa-exercise therapy in ankylosing spondylitis: a randomized controlled trial.
Van Tubergen A; Boonen A; Landewé R; Rutten-Van Mölken M; Van Der Heijde D; Hidding A; Van Der Linden S
Arthritis Rheum; 2002 Oct; 47(5):459-67. PubMed ID: 12382292
[TBL] [Abstract][Full Text] [Related]
20. Cost effectiveness of etoricoxib versus celecoxib and non-selective NSAIDS in the treatment of ankylosing spondylitis.
Jansen JP; Gaugris S; Choy EH; Ostor A; Nash JT; Stam W
Pharmacoeconomics; 2010; 28(4):323-44. PubMed ID: 20222755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
